Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial
Modern Rheumatology · 2026
DOI: 10.1093/mr/roag011 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Modern Rheumatology, 2026. Verfasst von Shoichi Fukui und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Hauptthemen laut MEDLINE: Pyridines, Triazoles, Castleman Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences, Inc..
Abstract (Originalsprache)
Objective
To evaluate the long-term safety and exploratory efficacy of filgotinib, a JAK1-preferential inhibitor, in patients with idiopathic multicentric Castleman disease (iMCD) over 52 weeks in a small, single-arm extension study.
Methods
This Phase Ib single-arm extension study enroled five patients with iMCD who completed an initial 8 weeks’ treatment with filgotinib. Patients received filgotinib 200 mg once daily for an additional 44 weeks (total 52 weeks). The primary endpoints assessed the comprehensive safety parameters. The secondary endpoints were efficacy.
Results
All five patients completed the full 52-week treatment period without permanent discontinuation. No serious adverse events or deaths were observed. All adverse events were mild-to-moderate (Grade 1-2), with upper respiratory infections in four patients and headache in three of five patients. Herpes zoster occurred in one patient. At Week 52, three of five patients had ≥1-point CHAP score reduction (one additional patient compared with Week 8). Median changes from baseline included: C-reactive protein −1.85 mg/dl, haemoglobin +0.50 g/dl, albumin +0.30 g/dl, and ECOG-PS zero points.
Conclusion
Filgotinib was well-tolerated over 52 weeks with no serious adverse events reported. Numerical changes in disease activity markers were observed over time, providing preliminary support for the therapeutic concept of JAK inhibition in iMCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
- Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
- Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe, Kobe, Japan.
ORCID-Profile: Shoichi Fukui
Förderung
- Gilead Sciences, Inc.
Zitieren
APA
Fukui, S., Sumiyoshi, R., Koga, T., Hosogaya, N., Narita, S., Morimoto, S., Kamisawa, O., Kiya, R., Katsube, A., Yano, S., Matsuyama, K., Kato, N., Kawamoto, A., & Kawakami, A. (2026). Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial. Modern Rheumatology. https://doi.org/10.1093/mr/roag011
Vancouver
Fukui S, Sumiyoshi R, Koga T, Hosogaya N, Narita S, Morimoto S, et al. Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial. Modern Rheumatology. 2026. doi:10.1093/mr/roag011
BibTeX
@article{Fukui2026,
author = {Fukui, Shoichi and Sumiyoshi, Remi and Koga, Tomohiro and Hosogaya, Naoki and Narita, Sawana and Morimoto, Shimpei and Kamisawa, Osamu and Kiya, Rieko and Katsube, Atsushi and Yano, Shingo and Matsuyama, Kazuko and Kato, Naoki and Kawamoto, Atsuhiko and Kawakami, Atsushi},
title = {Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial},
journal = {Modern Rheumatology},
year = {2026},
doi = {10.1093/mr/roag011}
}
EUVIMED